©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2015; 21(29): 8811-8816
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim, Se Hoon Park, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, South Korea
Author contributions: Kim SM performed the research; Park SH designed the research and wrote the paper.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Correspondence to: Se Hoon Park, MD, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, South Korea. hematoma@skku.edu
Telephone: +82-2-34103459 Fax: +82-2-34101754
Received: January 22, 2015
Peer-review started: January 24, 2015
First decision: March 10, 2015
Revised: March 23, 2015
Accepted: June 16, 2015
Article in press: June 16, 2015
Published online: August 7, 2015
Processing time: 197 Days and 23.5 Hours
Peer-review started: January 24, 2015
First decision: March 10, 2015
Revised: March 23, 2015
Accepted: June 16, 2015
Article in press: June 16, 2015
Published online: August 7, 2015
Processing time: 197 Days and 23.5 Hours
Core Tip
Core tip: There no evidence to date that chemotherapy beyond second-line has a beneficial effect in patients with gastric cancer. The impact of third- and subsequent lines of chemotherapy on survival and quality of life is the subject of this review.